Abbott announced today that it agreed to put nearly $6 billion on the table for diagnostics giant Alere. The company claims that with this acquisition it aims to become the leading point-of-care testing provider with annual sales of more than $7 billion.
Abbott has agreed to pay $56 per share for Alere, which marks a 51 percent premium over the closing prices for Alere shares just days ago.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Alere’s complementary portfolio of products, particularly with a focus on molecular diagnostics to detect influenza, is expected to provide Abbott access to new channels and geographies, including entry into fast-growing outlets, such as doctors’ offices, clinics, pharmacies and at-home testing.
Abbott said in a company statement that the deal will immediately add to earnings, but the agreement calls for Abbott to take on some $2.6 million in Alere debt. Evercore advised Abbott on the buyout, with Kirkland & Ellis providing legal counsel. JP Morgan advised Alere, with Cravath, Swaine & Moore as legal counsel.
Photo: Flickr user rosemary